In a significant advancement for cancer care, the U.S. Food and Drug Administration (FDA) has approved an injectable version ...

Ipilimumab + nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Dedifferentiated Liposarcoma.

Ipilimumab + nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Ovarian Cancer.

Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why ...

Becomes the first subcutaneously administered PD-1 inhibitor.

The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...

The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo Qvantig for ...

The FDA has approved an injectable version of the cancer drug Opdivo by Bristol Myers Squibb. Meanwhile, Axsome's Alzheimer's ...

Technology, a leading innovator in the orthodontics industry, is thrilled to announce the launch of its new Disney-licensed product - Smartee Ge Clear Aligner packages featuring Disney IP Mickey Mouse ...

Halozyme (HALO) announced that Bristol Myers Squibb (BMY) received FDA approval for Opdivo Qvantig co-formulated with Halozyme’s Enhanze drug ...

Opdivo Qvantig (nivolumab and hyaluronidase) has been approved for use across almost all of Opdivo's lengthy list of ...

(RTTNews) - Halozyme Therapeutics, Inc. (HALO) Monday said that the Food and Drug Administration (FDA) has approved Bristol Myers Squibb's Opdivo Qvantig co-formulated with Halozyme's ENHANZE drug ...